Trade Verve Therapeutics, Inc. - VERV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6.85 |
| Open | 6.74 |
| 1-Year Change | -59.86% |
| Day's Range | 6.51 - 6.86 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2024 | 6.85 | -0.02 | -0.29% | 6.87 | 7.38 | 6.79 |
| Apr 22, 2024 | 6.88 | 0.20 | 2.99% | 6.68 | 7.00 | 6.43 |
| Apr 19, 2024 | 6.62 | 0.08 | 1.22% | 6.54 | 6.75 | 6.40 |
| Apr 18, 2024 | 6.63 | -0.05 | -0.75% | 6.68 | 6.84 | 6.50 |
| Apr 17, 2024 | 6.72 | -0.43 | -6.01% | 7.15 | 7.25 | 6.70 |
| Apr 16, 2024 | 7.10 | -0.02 | -0.28% | 7.12 | 7.24 | 7.00 |
| Apr 15, 2024 | 7.27 | -0.42 | -5.46% | 7.69 | 7.69 | 7.11 |
| Apr 12, 2024 | 7.57 | -0.33 | -4.18% | 7.90 | 7.93 | 7.52 |
| Apr 11, 2024 | 8.03 | -0.25 | -3.02% | 8.28 | 8.28 | 7.89 |
| Apr 10, 2024 | 7.97 | -0.23 | -2.80% | 8.20 | 8.25 | 7.82 |
| Apr 9, 2024 | 8.73 | 0.33 | 3.93% | 8.40 | 8.73 | 8.34 |
| Apr 8, 2024 | 8.36 | -0.27 | -3.13% | 8.63 | 8.63 | 8.21 |
| Apr 5, 2024 | 8.49 | 0.17 | 2.04% | 8.32 | 8.71 | 8.15 |
| Apr 4, 2024 | 8.64 | -0.18 | -2.04% | 8.82 | 9.18 | 8.61 |
| Apr 3, 2024 | 8.67 | 0.29 | 3.46% | 8.38 | 8.88 | 8.15 |
| Apr 2, 2024 | 8.29 | -0.37 | -4.27% | 8.66 | 9.22 | 7.34 |
| Apr 1, 2024 | 12.74 | -0.34 | -2.60% | 13.08 | 13.08 | 12.51 |
| Mar 28, 2024 | 13.23 | 0.26 | 2.00% | 12.97 | 13.60 | 12.92 |
| Mar 27, 2024 | 13.16 | 0.25 | 1.94% | 12.91 | 13.21 | 12.63 |
| Mar 26, 2024 | 12.75 | -0.46 | -3.48% | 13.21 | 13.35 | 12.74 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Verve Therapeutics, Inc. Company profile
About Verve Therapeutics Inc
Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Verve Therapeutics Inc revenues was not reported. Net loss increased from $45.7M to $120.3M. Higher net loss reflects Fair Value of antidilution rights increase from $5.4M to $25.6M (expense), Fair Value Adjustment of success payment increase from $2.4M to $7.8M (expense), Interest Income - Non Bank decrease of 12% to $142K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
201 Brookline Avenue
Suite 601
BOSTON
MASSACHUSETTS 02215
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com